Microbot Medical (NASDAQ:MBOT) Stock Rating Upgraded by Wall Street Zen

Microbot Medical (NASDAQ:MBOT) was upgraded by research analysts at Wall Street Zen from a “strong sell” rating to a “sell” rating in a research report issued to clients and investors on Saturday, Wall Street Zen reports.

Several other research analysts have also recently weighed in on the stock. Loop Capital set a $4.00 price target on shares of Microbot Medical in a report on Wednesday, June 3rd. HC Wainwright restated a “buy” rating on shares of Microbot Medical in a report on Wednesday, August 19th. Zacks Research cut shares of Microbot Medical from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Microbot Medical in a research note on Wednesday, July 8th. Finally, B. Riley Financial started coverage on Microbot Medical in a report on Friday, September 11th. They set a “buy” rating and a $4.00 target price for the company. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $6.38.

Microbot Medical Price Performance

NASDAQ:MBOT opened at $1.36 on Friday. Microbot Medical has a fifty-two week low of $1.35 and a fifty-two week high of $3.74. The stock has a market capitalization of $91.35 million, a PE ratio of -5.67 and a beta of 1.03. The business’s 50-day simple moving average is $1.62 and its 200-day simple moving average is $1.96.

Microbot Medical (NASDAQ:MBOT) last issued its quarterly earnings data on Tuesday, August 11th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.08). The business had revenue of $0.24 million during the quarter, compared to analyst estimates of $0.13 million. On average, research analysts expect that Microbot Medical will post -0.3 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of MBOT. CTC Alternative Strategies Ltd. bought a new position in shares of Microbot Medical during the first quarter worth approximately $28,000. Cetera Investment Advisers increased its holdings in Microbot Medical by 44.7% in the 1st quarter. Cetera Investment Advisers now owns 42,412 shares of the biotechnology company’s stock valued at $102,000 after buying an additional 13,099 shares during the period. Private Advisor Group LLC acquired a new position in shares of Microbot Medical in the 1st quarter valued at approximately $54,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of Microbot Medical in the 4th quarter valued at approximately $65,000. Finally, Bank of America Corp DE raised its position in Microbot Medical by 1,688.1% during the first quarter. Bank of America Corp DE now owns 75,799 shares of the biotechnology company’s stock valued at $183,000 after purchasing an additional 71,560 shares in the last quarter. 16.30% of the stock is owned by institutional investors and hedge funds.

Microbot Medical Company Profile

Microbot Medical Inc is a medical-device company focused on developing robotic and computer-assisted technologies for minimally invasive vascular procedures. The company’s primary product candidate is the LIBERTY Endovascular Robotic System, a compact, single-use system designed to enable physicians to remotely control the navigation and positioning of guidewires and catheters during endovascular interventions.

LIBERTY is intended to support procedures involving the peripheral and coronary vasculature while potentially reducing physician exposure to radiation and improving procedural control.